ZEVRA THERAPEUTICS
Zevra Therapeutics is a development-stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company’s primary efforts include the development of safer, abuse-resistant opioid pain relievers. Its drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
ZEVRA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2006-01-01
Address:
Orlando, Florida, United States
Country:
United States
Website Url:
http://www.zevra.com
Total Employee:
11+
Status:
Active
Contact:
888.958.1253
Email Addresses:
[email protected]
Total Funding:
213.75 M USD
Technology used in webpage:
IPv6 MediaElement.js Akamai Hosted
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Revagenix
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-11-20 | Acer Therapeutics | Acer Therapeutics acquired by Zevra Therapeutics | N/A |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Debt - Zevra Therapeutics
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Zevra Therapeutics
Deerfield
Deerfield investment in Debt Financing - Zevra Therapeutics
BP Growth Partners
BP Growth Partners investment in Series B - Zevra Therapeutics
BP Growth Partners
BP Growth Partners investment in Series A - Zevra Therapeutics
Key Employee Changes
Official Site Inspections
http://www.zevra.com Semrush global rank: 2.72 M Semrush visits lastest month: 6.45 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zevra Therapeutics"
About Us | Zevra Therapeutics
Nov 24, 2024 Nimble and determined, Zevra pushes boundaries beyond what is possible to advance new therapies that meaningfully improve patients’ lives. The Zevra Story . Our Name. …See details»
Zevra Therapeutics Announces Organizational Changes
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no …See details»
Zevra Therapeutics - LinkedIn
Zevra Therapeutics today announced that members of Zevra’s executive leadership team will participate in a fireside chat at the Citizens Life Science Conference in New York, NY, on Wednesday ...See details»
Zevra Files Definitive Proxy Statement and Mails Letter
Apr 21, 2025 Information about Zevra’s executive officers and directors is available under the heading “Information about our Executive Officers and Directors” in Part I of Zevra’s Annual …See details»
Zevra Therapeutics - Crunchbase Company Profile
Zevra Therapeutics is a development-stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 6, 2024 To further Zevra’s transformation towards becoming a leading rare disease company, Zevra has begun executing its five-year vision to create value for patients and …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 6, 2024 To further Zevra’s transformation towards becoming a leading rare disease company, Zevra has begun executing its five-year vision to create value for patients and …See details»
Zevra Therapeutics - A rare approach to therapeutics.
We are a nimble rare disease therapeutics company comprised of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus with a proven record of bringing …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 9, 2024 Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited …See details»
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in …
Nov 20, 2023 The acquisition of Acer brings multiple rare disease assets and increases Zevra’s revenue potential with the addition of OLPRUVA ®, which is indicated for the treatment of …See details»
Zevra Details Strong Growth, Director Re-Election and Strategic …
Apr 21, 2025 Zevra Therapeutics, Inc. (NASDAQ: ZVRA) ("Zevra", or "the Company"), a commercial-stage company focused on providing therapies for people living with rare disease, …See details»
ZEVRA’S APPROACH We are driven by a patient-centric approach, …
Jan 8, 2024 Zevra’s patient advocacy engagement and collaborations in rare disease areas that we support, such as Idiopathic Hypersomnia (IH), Narcolepsy and Niemann-Pick Disease …See details»
Zevra Files Definitive Proxy Statement and Mails Letter to
Apr 21, 2025 Information about Zevra’s executive officers and directors is available under the heading “Information about our Executive Officers and Directors” in Part I of Zevra’s Annual …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 6, 2024 In a striving industry defined by rapid innovation and harsh competition, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) finds itself at a critical juncture. The company, dedicated …See details»
Press Releases | Zevra Therapeutics, Inc.
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million. 04-07-2025. Zevra Therapeutics Files Preliminary Proxy. 03-31-2025. Zevra Reports …See details»
Our Approach | Zevra Therapeutics
Like limitless unique and manifold zebra-stripe patterns, our perspective on drug development assumes that there are boundless pathways and infinite possibilities through which difficult …See details»
Zevra Reports First Quarter 2025 Financial Results and Corporate …
6 days ago Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million. Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive …See details»
Zevra Files Definitive Proxy Statement and Mails Letter to …
Apr 21, 2025 Zevra’s Board of Directors strongly recommends that stockholders vote "FOR" the Company's two highly-qualified directors up for re-election on the WHITE proxy card – Wendy …See details»
Zevra Files Definitive Proxy Statement and Mails Letter to ... - Nasdaq
Apr 21, 2025 Zevra’ s Board of Directors strongly recommends that stockholders vote "FOR" the Company's two highly-qualified directors up for re-election on the WHITE proxy card– Wendy …See details»
ZEvRA – Zero Emission electric Vehicles enabled by haRmonised …
To do so, ZEvRA will develop a Design for Circularity (DfC) methodology and a holistic circularity assessment aimed at improving the production of electric vehicles (EVs) based on the 9Rs. …See details»